Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: Focus on β2GPI-Specific T cell response

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 3, 2014, Pages 661-668

  Conti, Fabrizio ^a   Spinelli, Francesca Romana ^a   Alessandri, Cristiano ^a   Pacelli, Massimo ^a   Ceccarelli, Fulvia ^a   Marocchi, Elisa ^a   Montali, Anna ^a   Capozzi, Antonella ^a   Buttari, Brigitta ^b   Profumo, Elisabetta ^b   Sorice, Maurizio ^a   Arca, Marcello ^a   Valesini, Guido ^a   Riganò, Rachele ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Antiphospholipid syndrome; Atherosclerosis; Beta 2 glycoprotein I; Systemic lupus erythematosus

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; BETA 2-GLYCOPROTEIN I; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOANTIBODIES; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CELL DIVISION; ENDOTHELIUM, VASCULAR; FEMALE; HEMORHEOLOGY; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LIPOPROTEINS, HDL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONOCYTES; RISK FACTORS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; THROMBOPLASTIN; VASODILATION; YOUNG ADULT;

EID: 84894582292     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302680     Document Type: Article

References (63)

1. George C, Tsokos GC. Systemic Lupus Erythematosus. N Engl J Med. 2011; 365:2110-2121
2. Priori R, Medda E, Conti F, Cassara EA, Danieli MG, Gerli R, Giacomelli R, Franceschini F, Manfredi A, Pietrogrande M, Stazi MA, Valesini G. Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: A case-control study. Lupus. 2003;12:735-740
3. Govoni M, Bombardieri S, Bortoluzzi A, et al.; Italian Society of Rheumatology. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: Does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford). 2012;51:157-168
4. Margutti P, Sorice M, Conti F, Delunardo F, Racaniello M, Alessandri C, Siracusano A, Riganò R, Profumo E, Valesini G, Ortona E. Screening of an endothelial cDNA library identifies the C-Terminal region of Nedd5 as a novel autoantigen in systemic lupus erythematosus with psychiatric manifestations. Arthritis Res Ther. 2005;7:R896-R903
5. Valesini G, Alessandri C, Celestino D, Conti F. Anti-endothelial antibodies and neuropsychiatric systemic lupus erythematosus. Ann N Y Acad Sci. 2006;1069:118-128
6. Alessandri C, Barbati C, Vacirca D, Piscopo P, Confaloni A, Sanchez M, Maselli A, Colasanti T, Conti F, Truglia S, Perl A, Valesini G, Malorni W, Ortona E, Pierdominici M. T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J. 2012;26:4722-4732
7. Colasanti T, Maselli A, Conti F, Sanchez M, Alessandri C, Barbati C, Vacirca D, Tinari A, Chiarotti F, Giovannetti A, Franconi F, Valesini G, Malorni W, Pierdominici M, Ortona E. Autoantibodies to estrogen receptor α interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2012;64:778-787
8. Valesini G, Conti F. The persistent challenge of lupus nephritis. Clin Rev Allergy Immunol. 2011;40:135-137
9. Conti F, Alessandri C, Perricone C, Scrivo R, Rezai S, Ceccarelli F, Spinelli FR, Ortona E, Marianetti M, Mina C, Valesini G. Neurocognitive dysfunction in systemic lupus erythematosus: Association with antiphospholipid antibodies, disease activity and chronic damage. PLoS One. 2012;7:e33824
10. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients, and preventive practices. Medicine (Baltimore). 1992;71:291-302
11. Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study. Arthritis Rheum. 2009;61:1396-1402
12. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE-mechanisms and management. Nat Rev Rheumatol. 2012;8:214-223
13. Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, Satomura K, Ohsuzu F, Kurita A. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998;82:1535-1539
14. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: Testing and clinical relevance. Circulation. 2007;115:1285-1295
15. Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol. 2002;29:292-297
16. Kiss E, Soltesz P, Der H, Kocsis Z, Tarr T, Bhattoa H, Shoenfeld Y, Szegedi G. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun. 2006;27:211-217
17. Mak A, Liu Y, Ho RC. Endothelium-dependent but not endothelium- independent flow-mediated dilation is significantly reduced in patients with systemic lupus erythematosus without vascular events: A metaanalysis and metaregression. J Rheumatol. 2011;38:1296-1303
18. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003;62:1071-1077
19. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399-2406
20. Cacciapaglia F, Zardi EM, Coppolino G, Buzzulini F, Margiotta D, Arcarese L, Vadacca M, Amoroso A, Afeltra A. Stiffness parameters, intima-media thickness and early atherosclerosis in systemic lupus erythematosus patients. Lupus. 2009;18:249-256
21. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033-1044
22. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306
23. Alessandri C, Bombardieri M, Di Prospero L, Conigliaro P, Conti F, Labbadia G, Misasi R, Sorice M, Valesini G. Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. Clin Exp Immunol. 2005;140:173-180
24. Alessandri C, Sorice M, Bombardieri M, Conigliaro P, Longo A, Garofalo T, Manganelli V, Conti F, Esposti MD, Valesini G. Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis. Arthritis Res Ther. 2006;8:R180
25. Ortona E, Capozzi A, Colasanti T, Conti F, Alessandri C, Longo A, Garofalo T, Margutti P, Misasi R, Khamashta MA, Hughes GR, Valesini G, Sorice M. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood. 2010;116:2960-2967
26. Conti F, Alessandri C, Sorice M, Capozzi A, Longo A, Garofalo T, Misasi R, Bompane D, Hughes GR, Khamashta MA, Valesini G. Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome. Clin Exp Immunol. 2012;167:429-437
27. Jiménez S, García-Criado MA, Tàssies D, Reverter JC, Cervera R, Gilabert MR, Zambón D, Ros E, Bru C, Font J. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford). 2005;44:756-761
28. Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus. 2002;11:208-214
29. Medina G, Casaos D, Jara LJ, Vera-Lastra O, Fuentes M, Barile L, Salas M. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis. 2003;62:607-610
30. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: The honolulu heart program. Stroke. 2001;32:1701-1706
31. Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol. 2004;121:142-149
32. Miyakis S, Giannakopoulos B, Krilis SA. Beta 2 glycoprotein I-function in health and disease. Thromb Res. 2004;114:335-346
33. Müller G, Biering A, Lux E, Richter V. [Beta 2 glycoprotein I analysis in patients with hyperlipoproteinemia, arteriosclerotic occlusive disease and diabetes mellitus]. Z Gesamte Inn Med. 1983;38:282-284
34. Tincani A, Spatola L, Prati E, Allegri F, Ferremi P, Cattaneo R, Meroni P, Balestrieri G. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-Affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol. 1996;157:5732-5738
35. Aron AL, Cuellar RL, Brey RL, Meceown S, Espinoza LR, Shoenfeld Y. Early onset of autoimmunity in MLR/++ mice following immunization with beta2-glycoprotein I. Clin Exp Immunol. 1995; 101:78-82
36. Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun. 2008;30:74-83
37. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y. Autoantibody-mediated atherosclerosis. Autoimmun Rev. 2002;1:348-353
38. Gharavi AE, Summaritano LR, Wen J, Elkon EB. Induction of antiphospholipid antibodies by immunization with beta2-glycoprotein I (apolipoprotein H). J Clin Invest. 1992; 90:1105-1111
39. Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Palladini G, Valesini G. Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin Exp Immunol. 1999;115:214-219
40. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 1994;179:457-462
41. Visvanathan S, McNeil HP. Cellular immunity to beta 2-glycoprotein-1 in patients with the antiphospholipid syndrome. J Immunol. 1999;162: 6919-6925
42. Conti F, Sorice M, Circella A, Alessandri C, Pittoni V, Caronti B, Calderaro C, Griggi T, Misasi R, Valesini G. Beta-2-glycoprotein I expression on monocytes is increased in anti-phospholipid antibody syndrome and correlates with tissue factor expression. Clin Exp Immunol. 2003;132:509-516
43. Sorice M, Longo A, Capozzi A, Garofalo T, Misasi R, Alessandri C, Conti F, Buttari B, Riganò R, Ortona E, Valesini G. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum. 2007;56:2687-2697
44. Hattori N, Kuwana M, Kaburaki J, Mimori T, Ikeda Y, Kawakami Y. T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum. 2000;43:65-75
45. Buttari B, Profumo E, Mattei V, Siracusano A, Ortona E, Margutti P, Salvati B, Sorice M, Riganò R. Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response. Blood. 2005;106:3880-3887
46. Kuwana M, Matsuura E, Kobayashi K, Okazaki Y, Kaburaki J, Ikeda Y, Kawakami Y. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood. 2005;105:1552-1557
47. Profumo E, Buttari B, Alessandri C, Conti F, Capoano R, Valesini G, Salvati B, Riganò R. Beta2-glycoprotein I is a target of T cell reactivity in patients with advanced carotid atherosclerotic plaques. Int J Immunopathol Pharmacol. 2010;23:73-80
48. Kobayashi K, Kishi M, Atsumi T, Bertolaccini ML, Makino H, Sakairi N, Yamamoto I, Yasuda T, Khamashta MA, Hughes GR, Koike T, Voelker DR, Matsuura E. Circulating oxidized LDL forms complexes with beta2-glycoprotein I: Implication as an atherogenic autoantigen. J Lipid Res. 2003;44:716-726
49. George J, Harats D, Gilburd B, Afek A, Shaish A, Kopolovic J, Shoenfeld Y. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation. 2000;102:1822-1827
50. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, Barshack I, Kopolovic J, Shoenfeld Y. Immunolocalization of beta2-glycoprotein
51. George J, Shoenfeld Y, Harats D. The involvement of beta2-glycoprotein I (beta2-GPI) in human and murine atherosclerosis. J Autoimmun. 1999;13:57-60
52. George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, Levkovitz H, Shaish A, Goldberg I, Kopolovic J, Harats D, Shoenfeld Y. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation. 1998;98:1108-1115
53. Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost. 1999;81:87-95
54. Greco TP, Conti-Kelly AM, Greco T Jr, Doyle R, Matsuura E, Anthony JR, Lopez LR. Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Am J Clin Pathol. 2009;132:613-620
55. Ames PR, Delgado Alves J, Lopez LR, Gentile F, Margarita A, Pizzella L, Batuca J, Scenna G, Brancaccio V, Matsuura E. Antibodies against beta2-glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome. Clin Dev Immunol. 2006;13:1-9
56. Yamaguchi Y, Seta N, Kaburaki J, Kobayashi K, Matsuura E, Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Blood. 2007;110:4312-4318
57. Der H, Kerekes G, Veres K, Szodoray P, Toth J, Lakos G, Szegedi G, Soltesz P. Impaired endothelial function and increased carotid intimamedia thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus. 2007;16:497-503
58. Delgado Alves J, Kumar S, Isenberg DA. Cross-reactivity between anticardiolipin, anti-high-density lipoprotein and anti-Apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford). 2003;42:893-899
59. Haque S, Gordon C, Isenberg D, et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: The lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol. 2010;37:322-329
60. Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U, Witztum JL, Frostegård J. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104:1887-1893
61. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, Kuller LH. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:51-60
62. Ames PR, Antinolfi I, Scenna G, Gaeta G, Margaglione M, Margarita A. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost. 2009;7:537-542
63. Roman MJ, Salmon JE, Sobel R, Lockshin MD, Sammaritano L, Schwartz JE, Devereux RB. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol. 2001;87:663-666